Wave Life Sciences (WVE) Liabilities and Shareholders Equity (2014 - 2026)

Wave Life Sciences' Liabilities and Shareholders Equity history runs 13 years deep, the most recent figure standing at $583.5 million for Q1 2026.

• Quarterly Liabilities and Shareholders Equity rose 102.38% year-over-year to $583.5 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $1.7 billion (up 42.05% YoY) and the FY2025 annual result came in at $638.5 million, up 81.29% from the prior year.
• Liabilities and Shareholders Equity was $583.5 million for Q1 2026 at Wave Life Sciences, down from $638.5 million in the prior quarter.
• Across five years, Liabilities and Shareholders Equity topped out at $638.5 million in Q4 2025 and bottomed at $146.4 million in Q4 2022.
• A 5-year average of $284.7 million and a median of $241.4 million in 2025 frame the typical range for Liabilities and Shareholders Equity.
• Annual changes were most pronounced in 2025 — Liabilities and Shareholders Equity tumbled 32.67% — and 2026, when it surged 102.38%.
• Wave Life Sciences' Liabilities and Shareholders Equity stood at $146.4 million in 2022, then jumped by 87.82% to $274.9 million in 2023, then increased by 28.1% to $352.2 million in 2024, then surged by 81.29% to $638.5 million in 2025, then slipped by 8.61% to $583.5 million in 2026.
• Business Quant data shows WVE's Liabilities and Shareholders Equity at $583.5 million in Q1 2026, $638.5 million in Q4 2025, and $241.4 million in Q3 2025.